Key result
Heart failure admission therapy included ACE inhibitors or AT-II blockers in approximately 67%, diuretics in 70%, and beta-blockers in 33% of patients at a Swiss university hospital in 1998.
Observational
No
A 1998 snapshot of heart failure management at a Swiss university hospital demonstrated moderate utilization of guideline-directed medical therapies, highlighting the need for ongoing quality assessment.
1998 snapshot reveals historical GDMT gaps; leaves open the magnitude of subsequent improvements in heart failure care.
Similar to other countries, heart failure is a major cause of morbidity and mortality in Switzerland. Among heart failure patients admitted to a Swiss university hospital in 1998, admission therapy included: ACE inhibitors/AT-II blockers in approximately two-thirds; diuretics in approximately 70%; and beta-blockers in approximately one-third. Easy access to diagnostic tests and limited results of surveys suggest that quality of care of heart failure patients is satisfactory in Switzerland. However, results from ongoing studies are required to assess more reliably the quality of diagnosis and therapy of this high-risk population in Switzerland.
No takes yet. Share an insight, caveat, or question.
Muntwyler et al. (2000) conducted an observational in Heart failure. Heart failure admission therapy was evaluated on Admission therapy rates. Heart failure admission therapy included ACE inhibitors or AT-II blockers in approximately 67%, diuretics in 70%, and beta-blockers in 33% of patients at a Swiss university hospital in 1998.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: